相关实验视频

Updated: May 7, 2026

Induction of Drug-Induced, Autoimmune Hepatitis in BALB/c Mice for the Study of Its Pathogenic Mechanisms

Induction of Drug-Induced, Autoimmune Hepatitis in BALB/c Mice for the Study of Its Pathogenic Mechanisms

Published on: May 29, 2020

使用Icariin直接向S100A9可以抵消乙氨基引起的肝毒性

Pan Shen¹, Mei Xue², Zhishuo Hu³

¹Department of Rheumatology and Immunology, Zhongnan Hospital, Wuhan University, China; Department of Integrated Chinese Traditional and Western Medicine, Tongji Hospital, Tongji Medical College of Huazhong University of Science and Technology, China.

International immunopharmacology

|May 29, 2024

概括

伊卡林可以通过向S100A9.9来保护乙氨基诱导的肝损伤. 这种天然化合物通过p53,Nrf2和NF-κB通路减少肝损伤,亡和炎症.

科学领域:

肝病学肝病学是一种肝病学.
药理学药理学是指药理学的学科.
毒理学毒理学毒理学

背景情况:

乙氨基 (APAP) 过量服用是导致急性肝衰竭的主要原因,治疗选择有限.
伊卡林是一种来自Epimedium的天然化合物,表现出潜在的肝保护作用.
了解伊卡林对抗APAP诱导的肝损伤的机制对于开发新疗法至关重要.

研究的目的:

在小鼠中研究伊卡里因对乙氨基诱导的肝毒性产生保护作用.
阐明伊卡林肝脏保护作用的潜在分子机制.
为了确定伊卡林在减轻肝损伤中的潜在细胞点.

主要方法:

在服用乙氨基之前,小鼠接受了伊卡林或N-乙半氨酸 (NAC) 治疗.
通过测量血清酶,肝细胞亡和炎症标志物来评估肝毒性.
通过体外测试,西式涂抹,分子动力学和表面等离子体共振来探索分子机制,重点关注S100A9,p53,Nrf2和NF-κB通路.

主要成果:

伊卡林显著减轻了乙氨基引起的肝损伤,降低了血清酶水平和亡.
伊卡林通过调节p53,Nrf2和NF-κB信号通路来抑制肝细胞亡和炎症.
伊卡林直接向S100A9,其保护作用取决于S100A9的表达和功能.

结论:

伊卡里因对乙氨基诱导的肝损伤具有显著的肝保护作用.
该机制涉及针对S100A9和调节关键信号通路,包括p53,Nrf2和NF-κB.
伊卡林代表了对乙氨基诱导的肝毒性有前途的治疗候选者.

关键词:

乙氨基是一种肝毒性肝毒性肝毒性伊卡里恩是什么意思炎症反应是一种炎症反应.在S100A9A9中使用.

更多相关视频

An Intestine/Liver Microphysiological System for Drug Pharmacokinetic and Toxicological Assessment

An Intestine/Liver Microphysiological System for Drug Pharmacokinetic and Toxicological Assessment

Published on: December 3, 2020

Biosensor-based High Throughput Biopanning and Bioinformatics Analysis Strategy for the Global Validation of Drug-protein Interactions

Biosensor-based High Throughput Biopanning and Bioinformatics Analysis Strategy for the Global Validation of Drug-protein Interactions

Published on: December 1, 2020

相关概念视频

Effect of Hepatic Disease on Pharmacokinetics: Dose Adjustments Due to Hepatic Impairment

Effect of Hepatic Disease on Pharmacokinetics: Dose Adjustments Due to Hepatic Impairment

Hepatic impairment, characterized by decreased liver function, does not uniformly mandate adjustments in drug dosage. Whether dosage modifications are necessary depends on various factors related to the drug's metabolism and elimination pathways. If a drug is primarily excreted via the kidneys and bypasses significant hepatic processing, if it undergoes minimal metabolic transformation in the liver, or if it is volatile and primarily expelled through the lungs, dose adjustments may not be...